The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms. Recently, several cases of pancreatitis following lipid emulsion have been reported. One specific subset of this cohort we aim to study is the prevalence of pancreatitis following lipid emulsion therapy.
Authorship Criteria For Those Submitting Cases
Your participation in this study is very important to advancing our understanding of this novel treatment. Centers that contribute at least two completed data forms will have the opportunity to add one author per every two patients. Any center that completes one data form will be listed in the acknowledgements. Thus, if a center submits 4-5 complete data forms, they can pick two authors. If they submit 2-3 complete data forms, they will have one author. If they submit one, they will be listed in the acknowledgement section. If feasible, the authorship will include the statement "on behalf of the ToxIC investigators"
Each listed author is expected to: 1) make a substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data; 2) assist in drafting the paper or revising it critically for important intellectual content; and 3) give final approval of the version to be published.
Principal Investigator Contact Information
Michael Levine, MD
University of Southern California and Banner Good Samaritan Medical Center
and review the new lipid registry form